Cycle Design for Growth Hormone Secretagogues

Cycle design matters more for growth-hormone-axis peptides than for most other research-peptide classes. The GH axis is tightly regulated through multiple feedback loops (hypothalamic GHRH and somatostatin, pituitary somatotrophs, circulating IGF-1 negative feedback), and exogenous peptide stimulation interacts with all of them. Poorly designed cycles produce tachyphylaxis, IGF-1 drift, or somatotroph exhaustion. Well-designed cycles preserve response over the research-protocol duration. This article covers the biology behind both outcomes and the cycle patterns the primary literature supports.

The core distinction: growth hormone secretagogues (GHS) and GHRH analogues follow different pharmacology rules. Conflating the two produces the worst common mistakes in cycle design. Sigalos and Pastuszak’s 2018 Sex Med Rev review on GHS safety and efficacy ¹ is the best single-source framing for the class-level picture.

The two compound classes and their different cycle biology

GHS compounds (Ipamorelin, Hexarelin) act on the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons. They produce an acute GH pulse that’s superimposed on the endogenous pulsatile GH secretion pattern.

GHRH analogues (CJC-1295, Tesamorelin) act on the GHRH receptor on the same somatotrophs. They prime the cells for GH release in response to either endogenous GHS signalling or exogenous GHS administration, and in their longer-acting forms produce sustained baseline GH and IGF-1 elevation.

The cycle-relevant difference is in receptor-level kinetics after repeated exposure:

• GHS-R1a desensitises relatively quickly under sustained agonist exposure. Orkin and colleagues’ 2003 Journal of Endocrinology Investigation paper demonstrated this directly: rapid desensitisation of the ghrelin receptor to hexarelin in vitro within a timeframe consistent with the clinical tachyphylaxis observed in chronic hexarelin administration ⁴. The mechanism involves receptor internalisation, downregulation of receptor expression, and downstream signalling adaptation; all standard GPCR desensitisation pathways.
• GHRH receptor desensitises more slowly. Khorram and colleagues’ 1997 Journal of Clinical Endocrinology and Metabolism paper documented multi-month administration of GHRH(1-29) in age-advanced men and women with sustained endocrine and metabolic effects ⁵. This is not to say GHRH-R is desensitisation-resistant; it is less rapidly affected than GHS-R1a under equivalent dosing intensity.

The practical consequence: GHS compounds require more attention to cycle length and break periods to preserve response; GHRH analogues tolerate longer continuous dosing with IGF-1 and safety monitoring being the primary constraints rather than receptor desensitisation.

Why Ipamorelin is the chronic-cycle GHS of choice

The research preference for Ipamorelin over Hexarelin in chronic protocols has a specific pharmacological basis. Raun and colleagues’ 1998 European Journal of Endocrinology paper established Ipamorelin as the first selective GHS ². “Selective” in this context meant two things: selectivity for GH release (without the cortisol, prolactin, and ACTH elevations seen with earlier GHS compounds including hexarelin), and importantly a more moderate acute GH peak.

The second property matters for tachyphylaxis. Receptor desensitisation is not solely dose-dependent; it is also intensity-dependent. A compound producing a sharper, higher-amplitude peak drives more GHS-R1a internalisation per dose than a compound producing a lower, flatter response. Hexarelin’s strong acute GH peak is precisely what drives its rapid desensitisation; Ipamorelin’s more moderate peak extracts less receptor-level adaptation per dose, and the response is preserved over weeks of dosing.

This is the mechanistic basis for the 12-week-on / 4-week-off pattern commonly cited for Ipamorelin. After about 12 weeks of pulsatile GHS-R1a activation, some cumulative desensitisation begins to appear even with Ipamorelin’s selective profile. A 4-week break allows receptor resensitisation (downregulated receptors return to baseline expression levels, internalised receptors return to the membrane) before the next cycle.

For Hexarelin, the cycle is typically shorter: 4–8 weeks maximum before tachyphylaxis significantly attenuates response. Researchers using Hexarelin for acute-response work (single-dose or very short protocols) often avoid the cycling question entirely because tachyphylaxis doesn’t develop within a few doses.

CJC-1295 and the GHRH analog cycle consideration

CJC-1295 with DAC modification extends the half-life of the GHRH(1-29) sequence to approximately 8 days via covalent albumin binding. This produces sustained baseline GH and IGF-1 elevation, documented in Teichman and colleagues’ 2006 dose-ranging study ³.

The cycle considerations are different from GHS because the receptor biology is different:

• GHRH-R desensitisation is slow. Even under multi-week continuous CJC-1295 exposure, the GHRH receptor does not downregulate as rapidly as GHS-R1a under equivalent intensity.
• IGF-1 drift becomes the constraint. Sustained GH elevation over weeks drives IGF-1 elevation as well, and at research doses IGF-1 levels can drift upward over the cycle. Monitoring IGF-1 is more relevant for CJC-1295 cycles than for Ipamorelin cycles.
• Somatostatin feedback matters. Chronic GHRH-R activation feeds back through somatostatin elevation, which partially offsets the GH response. This is a slower adaptation than receptor-level desensitisation but becomes relevant over months of continuous administration.

The practical cycle pattern is similar to Ipamorelin’s (12 weeks on / 4 weeks off) but for different reasons. For Ipamorelin, the 4-week break is about receptor resensitisation. For CJC-1295 DAC, the 4-week break is more about letting IGF-1 return to baseline and resetting somatostatin feedback.

Tesamorelin and the registered-regimen anomaly

Tesamorelin is the FDA-approved GHRH analogue (for HIV-associated lipodystrophy). Its registered regimen is 2 mg/day SC continuously for 26 weeks, which is substantially longer than the 12 + 4 convention common in research-peptide cycles.

Why is it different? Two factors:

1. The clinical indication is different. HIV-associated lipodystrophy is a sustained metabolic problem requiring sustained treatment; the regulatory approval is for that indication, not for GH-axis research generally. The 26-week regimen reflects clinical-endpoint optimisation for visceral fat reduction, not a general statement that 26 weeks is optimal for all GHRH-analogue research.
2. Safety monitoring is clinical-grade. The registered indication includes regular IGF-1 monitoring, clinical follow-up, and dose adjustment if IGF-1 drifts above the upper limit of normal. Research protocols without equivalent monitoring infrastructure default to shorter, more conservative cycles.

The implication for research protocol design: Tesamorelin CAN be cycled longer than Ipamorelin or CJC-1295, but whether it SHOULD be depends on the research question and the monitoring available. Most research protocols match Tesamorelin cycling to the 12 + 4 convention unless the specific research question (visceral fat, liver fat) justifies the longer registered regimen.

Stack cycling: Ipamorelin + CJC-1295 DAC

The canonical GH-axis stack (Ipamorelin + CJC-1295) is typically cycled as a unit rather than with staggered schedules. Both compounds active for 12 weeks, both inactive for 4 weeks, then both active again.

The logic:

• Mechanism coordination. CJC-1295 drives baseline IGF-1 elevation; Ipamorelin adds pulsatile GH peaks on top of that elevated baseline. The combined profile is a coherent pharmacological state, and separating the two compounds’ cycles would produce asymmetric patterns (pulsatile without baseline, or baseline without pulsatile) that are harder to interpret in research terms.
• Break-period biology. Both receptor systems (GHS-R1a and GHRH-R) benefit from the 4-week break for their respective reasons (receptor resensitisation for GHS; IGF-1 and somatostatin reset for GHRH). Coordinated cycling addresses both.
• Practical scheduling. Running two staggered cycles is operationally more complex than running one coordinated cycle. Research protocol design benefits from the simpler schedule.

Within the active cycle, the two compounds are dosed on their respective schedules: Ipamorelin 2–3 times daily SC, CJC-1295 DAC once or twice weekly SC. The schedules are non-conflicting (different days, different times) and do not require coordination beyond the cycle-level synchronisation.

Tapering and rebuild

Neither Ipamorelin nor CJC-1295 has the kind of half-life profile that produces sharp withdrawal effects at cycle end. Both can be stopped abruptly without meaningful acute-withdrawal issues. The “tapering” concept sometimes imported from steroid-research protocols doesn’t apply in the same way.

What does matter across the cycle boundary:

• IGF-1 returns to baseline gradually over 1–3 weeks after CJC-1295 DAC cessation, reflecting the compound’s long half-life and the gradual decline of albumin-bound peptide concentration.
• Receptor resensitisation for GHS-R1a occurs over 2–4 weeks, matching the 4-week break duration. Shorter breaks may be insufficient for full receptor recovery.
• Somatostatin feedback resets over days to 1–2 weeks after GHRH-analogue cessation.

For subsequent cycles, “rebuild” is not typically a discrete concept. The next cycle simply begins at normal dosing on day 1 of week 17 (after the 4-week break ending week 16). Dose escalation across sequential cycles is occasionally seen in research protocols where the first cycle is a dose-finding exercise and subsequent cycles use the optimal dose identified.

Biomarker monitoring within the cycle

For research protocols that can include biomarker monitoring, three measurements are relevant:

1. IGF-1 at week 0, week 6, week 12. Baseline, mid-cycle, end-of-cycle. CJC-1295-containing cycles will show clear IGF-1 elevation; Ipamorelin-only cycles show more variable changes.
2. Fasting glucose and insulin at baseline and end-of-cycle. GH elevation produces insulin resistance as a known side effect; research protocols should track this even at research doses.
3. Cortisol at week 0 and week 8. Ipamorelin’s selectivity profile should preserve cortisol stability, but the measurement confirms selectivity in the specific research context.

These are not mandatory; many research protocols run without biomarker monitoring. When monitoring is available, it improves the interpretation of both mechanism and outcome data.

Common cycle-design mistakes

1. Extending Hexarelin cycles beyond 8 weeks. Tachyphylaxis ⁴ means response attenuates significantly beyond this point, and the research protocol is measuring a weaker pharmacological state at week 12 than at week 4. If longer cycling is needed, substitute Ipamorelin.

2. Treating CJC-1295 non-DAC and DAC the same way. The non-DAC variant (mod-GRF 1-29) has a half-life of ~30 minutes and is dosed multiple times daily. The DAC variant has a half-life of ~8 days and is dosed weekly. Cycle design for the two is not interchangeable. Most “CJC-1295” references in research literature default to the DAC variant; confirm which is in the protocol.

3. Running break-free chronic protocols across the GHS class. Sustained GHS-R1a activation for months without breaks produces progressive desensitisation that cannot be read through a short end-of-protocol measurement. The 4-week break is cheap insurance against this confound.

4. Assuming GHRH-analogue cycles can be run indefinitely. Khorram 1997 ⁵ supports multi-month GHRH administration with maintained response, but IGF-1 drift and long-term safety are monitoring concerns. Research protocols beyond 26 weeks continuous should include monitoring infrastructure comparable to the Tesamorelin clinical regimen.

5. Coordinating the stack at different cycle phases. Running Ipamorelin on a 12 + 4 cycle while running CJC-1295 on a 16 + 4 cycle, or any other asymmetric pattern, creates research protocols with interaction effects that are hard to attribute to either compound individually.

What the cycle-design literature does not settle

• Optimal cycle length for specific research endpoints remains under-studied. The 12 + 4 convention is reasonable but not empirically optimised for, say, lean-mass endpoints vs. recovery endpoints vs. metabolic endpoints.
• Individual variability in tachyphylaxis onset across Ipamorelin users. Some protocols show response preserved for 16+ weeks; others show attenuation by week 8. Genetic variation in GHS-R1a and downstream signalling may explain this, but it is not characterised well enough to guide individualised protocols.
• Safety of multi-year cycling. Research-peptide use at the time-scales relevant to multi-year cycling (8–10 cycles across 2–3 years) has limited published safety data. The Tesamorelin clinical experience supports multi-year use with monitoring; extrapolating to research-peptide compounds without equivalent monitoring infrastructure is not directly supported.

Where to order

Buy Ipamorelin, buy CJC-1295, buy Tesamorelin, or buy Hexarelin from Thailand Peptides through the Bangkok research desk. Standard 5 mg vials (Ipamorelin, Hexarelin) and 2 mg vials (CJC-1295 DAC, Tesamorelin), ≥98% HPLC purity, supplier COA on file. For stack orders (the canonical Ipamorelin + CJC-1295 pairing), WhatsApp for combined pricing.

For the class pharmacology, see the Ipamorelin vs CJC-1295 mechanism deep-dive. For the broader GH-axis research landscape, see best peptides for muscle growth.